The integration of artificial intelligence is transforming how drug manufacturers anticipate market needs, allowing for a level of accuracy in demand planning that was previously unattainable through traditional statistical methods.

The transition toward evidence-based decision making is enabling pharmaceutical organizations to synchronize production with real-world demand, reducing waste and ensuring that life-saving medications are always available when and where they are needed.

Navigating the complexities of pharmaceutical distribution requires a fundamental shift from traditional reactive models to robust, proactive strategies that prioritize long-term stability and patient safety over short-term cost savings.

NVIDIA and Eli Lilly and Company have announced the creation of a new NVIDIA-Lilly AI lab, designed to apply artificial intelligence to some of...